Tag-Archive for ◊ JNJ ◊

• Friday, January 24th, 2014

Johnson & Johnson subsidiary Codman Neuro’s recall of its Trufill n-BCA liquid embolic system gets labeled as a Class I measure by the FDA. Codman Neuro, a division of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes, said the FDA labeled its Trufill n-BCA liquid embolic system recall as Class I, the federal watchdog agency’s highest-risk classification. The […]

• Thursday, January 23rd, 2014

Jan 21 (Reuters) – Healthcare company Johnson & Johnson cautioned Tuesday that prescription-drug sales would likely lose some momentum this year and forecast 2014 earnings at the lower end of Wall Street expectations, sending its shares down almost 2 percent. Chief Financial Officer Dominic Caruso cautioned that the growth rate of prescription drug sales will “decelerate” this […]

• Saturday, November 23rd, 2013

A New Jersey judge warned of several “rogue websites” by lawyers seeking to take advantage of Johnson & Johnson (JNJ)’s agreement to pay at least $2.47 billion to settle thousands of lawsuits over its recalled hip implants. Superior Court Judge Brian Martinotti heard a summary in Hackensack today of the settlement from lawyers who negotiated an […]

• Thursday, November 21st, 2013

A unit of Johnson & Johnson has agreed to pay an estimated $2.5 billion to settle thousands of lawsuits from individuals allegedly injured by the company’s artificial hip implants, the company announced Tuesday. The settlement, announced during a hearing in federal court in Ohio on Tuesday, would compensate an estimated 8,000 patients who underwent surgery […]

• Friday, November 15th, 2013

Johnson & Johnson officials reveal to MassDevice.com plans to restructure its diabetes division to “get in front” of pricing and reimbursement pressures, saying an unspecified number of layoffs will occur. Johnson & Johnson (NYSE:JNJ) told MassDevice.com today that it plans to make an unspecified number of job cuts, consolidate facilities and change the reporting structure on some of the sales […]

• Thursday, November 14th, 2013

Johnson & Johnson has tentatively agreed to a settlement that could reach up to $4 billion to resolve thousands of lawsuits filed by patients injured by a flawed all-metal replacement hip, said two lawyers briefed on the plan. The tentative plan, which must win court approval, represents one of the largest payouts for product liability […]

• Friday, November 08th, 2013

Johnson & Johnson will pay $2.2 billion to the U.S. government to end multiple investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses, a person familiar with the settlement said on Monday. The settlement with the company and its subsidiaries covers the marketing of schizophrenia treatment Risperdal and of heart drug […]

• Wednesday, October 16th, 2013

Johnson & Johnson has traditionally had a strong medical device and diagnostics sectors but the growth in both of those areas has slowed. In the second quarter of 2013, the device segment grew at a rate of 0.5%—ignoring the Synthes acquisition and currency fluctuations. The company is rumored to be mulling the sale of its […]

• Tuesday, October 15th, 2013

The year-old collaboration between DePuy Synthes Spine and Brainlab now includes co-marketing a new product, in addition to continued development on surgical navigation and imaging devices. Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes Spine said it’s expanding its collaboration with Brainlab on surgical navigation and imaging devices, in addition to co-marketing Brainlab’s Airo Mobile Intraoperative […]

• Friday, October 11th, 2013

Johnson & Johnson’s DePuy Synthes subsidiary goes after a trio of ex-sales reps now working for rival Globus Medical in Texas. DePuy Synthes, the orthopedics arm of Johnson & Johnson (NYSE:JNJ), sued rival Globus Medical (NYSE:GMED) and 3 ex-DePuy sales reps now working for Globus, accusing them of breaching their contracts with their defections. It’s the latest lawsuit filed […]